Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study.
Sarah BitarNathalie ThillyNelly AgrinierPublished in: European journal of clinical pharmacology (2021)
In an unselected population-based sample of HFpEF patients, the long-term stable use of the combination ACEI/ARB and BB, BB exclusively, ACEI/ARB exclusively, or the combination ACEI/ARB and BB and MRAs was associated with reduced three-year all-cause mortality.
Keyphrases
- ejection fraction
- aortic stenosis
- heart failure
- growth factor
- end stage renal disease
- recombinant human
- chronic kidney disease
- healthcare
- depressive symptoms
- left ventricular
- emergency department
- peritoneal dialysis
- type diabetes
- coronary artery disease
- cardiac resynchronization therapy
- adverse drug
- acute heart failure